Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections

Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858.

Abstract

  1. Neutralization of IFN-γ with emapalumab can reverse severe, refractory hemophagocytic lymphohistiocytosis.

  2. Neutralizing IFN-γ did not impair control of multiple viral and other infections in a severely ill patient.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / administration & dosage
  • Antibodies, Neutralizing / adverse effects
  • Antibodies, Neutralizing / therapeutic use*
  • Cytokines / metabolism
  • Drug Resistance
  • Humans
  • Infant
  • Infections / diagnosis
  • Infections / etiology
  • Inflammation Mediators / metabolism
  • Interferon-gamma / antagonists & inhibitors
  • Lymphohistiocytosis, Hemophagocytic / complications
  • Lymphohistiocytosis, Hemophagocytic / diagnosis
  • Lymphohistiocytosis, Hemophagocytic / metabolism
  • Lymphohistiocytosis, Hemophagocytic / therapy*
  • Male
  • Severity of Illness Index
  • Treatment Outcome
  • Viremia / diagnosis
  • Viremia / etiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Cytokines
  • Emapalumab
  • Inflammation Mediators
  • Interferon-gamma